Ozempic, Wegovy & Zepbound: Can Weight Loss Drugs Protect Your Heart?

Ozempic, Wegovy & Zepbound: Can Weight Loss Drugs Protect Your Heart?

Ozempic, Wegovy, and Zepbound have become household names. Millions of Americans use these weight loss drugs, and they’re reshaping how doctors treat obesity and diabetes. But for cardiologists, the bigger story isn’t the number on the scale. It’s what these medications can do for the heart.

Large clinical trials now show that some of these drugs lower the risk of heart attack, stroke, and heart failure complications. Here’s what the evidence shows, who may benefit, and what you should know before starting one.

How GLP-1 Weight Loss Drugs Work

These medications mimic natural gut hormones that are released after you eat:

  • Semaglutide (Ozempic, Wegovy and the Wegovy pill) mimics a hormone called GLP-1.
  • Tirzepatide (Mounjaro and Zepbound) mimics two hormones, GLP-1 and GIP, which is why it’s called a “dual agonist.”

They slow stomach emptying, help you feel full sooner, reduce cravings, and help the body manage blood sugar. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound contain the same active ingredients and are approved for weight management.

GLP-1 & Gut Microbiome: What Science Shows About Metabolism

How Weight Loss Drugs May Protect the Heart

The heart benefits appear to come from more than weight loss alone. These drugs also:

  • Lower blood pressure
  • Improve blood sugar and insulin resistance
  • Reduce inflammation in blood vessels
  • Improve cholesterol and triglyceride levels
  • Reduce fat around the heart and organs
  • Ease strain on the heart in people with heart failure

What the Research Shows

Wegovy (semaglutide): fewer heart attacks and strokes. The landmark SELECT trial followed 17,604 adults with overweight or obesity and existing heart disease, but without diabetes, for up to five years. Those taking semaglutide had a 20% lower risk of heart attack, stroke or cardiovascular death than those taking a placebo. Based on this trial, Wegovy became the first weight loss drug FDA-approved to reduce cardiovascular risk. The Wegovy pill, approved in December 2025, carries the same heart indication.

Ozempic (semaglutide): heart protection in diabetes. In people with type 2 diabetes and high cardiovascular risk, semaglutide also lowered the risk of major heart events, and Ozempic is approved to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.

Zepbound (tirzepatide): heart failure benefit. The SUMMIT trial studied 731 people with obesity and heart failure with preserved ejection fraction (HFpEF), a common form of heart failure in which the heart is stiff rather than weak. Tirzepatide reduced the risk of cardiovascular death or worsening heart failure by 38%, and cut heart failure hospitalizations by more than half. Patients lost about 14% of their body weight and reported better symptoms and ability to exercise.

Mounjaro (tirzepatide): newly approved for heart protection. The SURPASS-CVOT trial compared tirzepatide with another GLP-1 drug, dulaglutide (Trulicity), in more than 13,000 people with type 2 diabetes and heart disease. Tirzepatide had about 8% fewer heart attacks, strokes and cardiovascular deaths. That difference met the trial’s goal of showing it was at least as protective, but it wasn’t large enough to prove it was better. In August 2026, the FDA approved Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.

What we don’t know yet. As of this writing, Zepbound isn’t FDA-approved specifically to treat heart failure or to reduce heart attack and stroke risk, though its active ingredient has shown heart benefits in trials and more research is ongoing. Newer pills, such as Foundayo (orforglipron), are approved for weight management but don’t yet have heart outcome data.

Ozempic vs. Wegovy vs. Zepbound vs. Mounjaro

BrandActive ingredientHow it's takenFDA-approved forHeart-related approval
OzempicSemaglutideWeekly injectionType 2 diabetesReduces heart attack, stroke and CV death in type 2 diabetes with heart disease
WegovySemaglutideWeekly injection or daily pillWeight managementReduces heart attack, stroke and CV death in people with overweight or obesity and heart disease
MounjaroTirzepatideWeekly injectionType 2 diabetesReduces major cardiovascular events in type 2 diabetes with heart disease (August 2026)
ZepboundTirzepatideWeekly injectionWeight management, obstructive sleep apneaNo specific heart indication yet

Who May Benefit Most From Weight Loss Drugs for Heart Health?

Talk with your doctor about whether one of these medications is right for you if you have:

  • Existing heart disease, such as a prior heart attack, stroke, stent, bypass or peripheral artery disease, along with overweight or obesity
  • Type 2 diabetes with heart disease or high cardiovascular risk. Learn how diabetes increases heart disease risk.
  • Heart failure with preserved ejection fraction and obesity
  • Obesity with other risk factors, such as high blood pressure, sleep apnea or high cholesterol

These drugs are prescribed for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. They aren’t meant for cosmetic weight loss.

Side Effects and Safety

Most side effects are digestive and usually improve as your body adjusts:

  • Nausea, vomiting, diarrhea or constipation, especially when the dose is increased
  • Feeling full quickly or a reduced appetite
  • Reflux or heartburn

Less common but more serious risks include gallbladder problems, pancreatitis and dehydration that can strain the kidneys. These drugs carry a warning about a rare type of thyroid tumor and aren’t recommended for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.

A few other important points

  • Muscle loss: Some of the weight lost can be muscle. Strength training and enough protein help preserve it. See our guide to heart-healthy exercises.
  • Surgery and procedures: These drugs slow stomach emptying, which can raise the risk of aspiration during anesthesia. Tell your surgical team you take one. See our post on cardiac clearance before surgery.
  • Compounded or online versions: Unapproved copies may contain the wrong dose or unknown ingredients. Use FDA-approved products from a licensed pharmacy.
  • Stopping the medication: Most people regain much of the weight after stopping, and heart benefits likely depend on continued treatment.
Ozempic Side Effects: What to Expect & How to Manage

What Weight Loss Drugs Don't Replace

These medications are a powerful new tool, but they work best alongside proven heart care, not instead of it:

  • Statins and other cholesterol medications remain essential for people with heart disease. Read statin myths vs. facts.
  • Blood pressure control, regular exercise, a heart-healthy diet and not smoking remain the foundation of prevention.
  • Regular cardiology follow-up helps track how your heart responds as your weight, blood pressure and blood sugar change. Some medications, such as blood pressure and diabetes drugs, may need to be reduced as you lose weight.

Frequently Asked Questions

Do weight loss drugs lower the risk of heart attack? For certain people, yes. In the SELECT trial, Wegovy reduced the risk of heart attack, stroke, and cardiovascular death by 20% in adults with overweight or obesity and existing heart disease. Ozempic and Mounjaro are approved to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.

Is Zepbound better than Wegovy for the heart? There’s no head-to-head heart outcome trial comparing them in people without diabetes. Tirzepatide (Zepbound) generally produces more weight loss, but Wegovy currently has the stronger, FDA-approved evidence for preventing heart attacks and strokes in people with heart disease. The best choice depends on your health, insurance coverage and goals.

Are these drugs safe if I have heart disease? For most people with heart disease, yes. In fact, people with heart disease were the focus of the major heart trials. These drugs can cause a small increase in resting heart rate, so your cardiologist should review your full medication list and heart history before you start.

Will insurance cover Wegovy or Zepbound? Coverage varies widely. Some plans, including some Medicare Part D plans, cover Wegovy for cardiovascular risk reduction in people with heart disease, even if they don’t cover drugs for weight loss alone. Check with your plan, and ask your doctor whether a prior authorization is needed.

Can I stop taking it once I lose the weight? Most people regain much of the weight after stopping, and heart benefits likely depend on staying on treatment. Talk with your doctor before stopping or lowering your dose.

Talk With a Cardiologist About Weight Loss Medications in Tampa

If you have heart disease, diabetes or obesity and are wondering whether a GLP-1 medication could protect your heart, we can help. Our board-certified cardiologist will review your heart risk, your current medications and the latest evidence to help you decide whether a weight loss drug fits into your heart care plan, and coordinate with your primary care doctor or endocrinologist.

Request an appointment or call (814) 540-4322.

602 S Audubon Ave, Suite A, Tampa, FL 33609

Medical Disclaimer

The content provided on the Ascent Cardiology website is intended for general educational and informational purposes only. The information, articles, and media presented on this website do not constitute medical advice, diagnosis, or treatment recommendations. Content published on this website is not intended to replace consultation, evaluation, or treatment by qualified healthcare professionals, including the providers at Ascent Cardiology or other licensed medical professionals.

If you believe you may be experiencing a medical emergency, call 911 or seek immediate emergency medical care.

The medical information, opinions, and educational materials presented on this website are provided for general awareness and may not reflect the specific clinical practices or medical opinions of Ascent Cardiology or its providers. Reliance on any information provided on this website is solely at your own risk.

This website may include links to third-party medical or educational websites for informational purposes only. Ascent Cardiology does not control, endorse, or assume responsibility for the accuracy, reliability, or content of any third-party websites linked from this site.

Sources